间充质干细胞治疗可缓解干燥综合征症状
发表者：智良
日期：2015-03-04
浏览次数：533
评论次数：0
摘要: 干燥综合征(SS)是一种系统性自身免疫性疾病，其特征为眼部及口腔干燥，其分子及细胞学发病机制非常复杂。本研究首次发现SS患者及具有SS样病变的NOD/Ltj小鼠的骨髓间充质干细胞存在免疫调节功能缺陷。更重要的是，使用间充质干细胞(MSC)治疗可抑制小鼠模型及SS患者的自身免疫，并恢复唾液腺的分泌功能。MSC治疗可引导T细胞分化为Treg细胞及Th2细胞，从而抑制Th17及Tfh反应，并缓解疾病症状。输入的MSCs可向炎症反应部位迁移，而中和基质细胞衍生因子-1 (SDF-1)的配体CXCR4可消除其疗效，说明该迁移是SDF-1依赖的。综上，本研究说明MSC的免疫调节功能在SS发病中有重要作用，而同种异体MSC治疗可能是一种全新、有效、安全的SS治疗方法。
附原文:Sjogren syndrome (SS) is a systemic autoimmune disease characterized by dry mouth and eyes, and the cellular and molecular mechanisms for its pathogenesis are complex. Here we reveal, for the first time, that bone marrow mesenchymal stem cells in SS-like NOD/Ltj mice and human patients were defective in immunoregulatory functions. Importantly, treatment with mesenchymal stem cells (MSCs) suppressed autoimmunity and restored salivary gland secretory function in both mouse models and SS patients. MSC treatment directed T cells toward Treg and Th2, while suppressing Th17 and Tfh responses, and alleviated disease symptoms. Infused MSCs migrated toward the inflammatory regions in a stromal cell–derived factor-1–dependent manner, as neutralization of stromal cell–derived factor-1 ligand CXCR4 abolished the effectiveness of bone marrow mesenchymal stem cell treatment. Collectively, our study suggests that immunologic regulatory functions of MSCs play an important role in SS pathogenesis, and allogeneic MSC treatment may provide a novel, effective, and safe therapy for patients with SS. This study was registered atwww.clinicaltrials.gov as NCT00953485.
引自: Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood. 2012; 120(15): 3142-3151. （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）
附原文:Sjogren syndrome (SS) is a systemic autoimmune disease characterized by dry mouth and eyes, and the cellular and molecular mechanisms for its pathogenesis are complex. Here we reveal, for the first time, that bone marrow mesenchymal stem cells in SS-like NOD/Ltj mice and human patients were defective in immunoregulatory functions. Importantly, treatment with mesenchymal stem cells (MSCs) suppressed autoimmunity and restored salivary gland secretory function in both mouse models and SS patients. MSC treatment directed T cells toward Treg and Th2, while suppressing Th17 and Tfh responses, and alleviated disease symptoms. Infused MSCs migrated toward the inflammatory regions in a stromal cell–derived factor-1–dependent manner, as neutralization of stromal cell–derived factor-1 ligand CXCR4 abolished the effectiveness of bone marrow mesenchymal stem cell treatment. Collectively, our study suggests that immunologic regulatory functions of MSCs play an important role in SS pathogenesis, and allogeneic MSC treatment may provide a novel, effective, and safe therapy for patients with SS. This study was registered atwww.clinicaltrials.gov as NCT00953485.
引自: Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood. 2012; 120(15): 3142-3151. （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）